Prednisolone acetate is a prednisolone molecule bound to an acetate functional group by an ester bond.
Prednisolone acetate was granted FDA approval in 1955.
Prednisolone acetate is indicated as an anti-inflammatory or immunosuppressive agent for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, or infectious conditions. Prednisolone acetate is also indicated in organ transplant patients, as well as endocrine or neoplastic conditions.
Children's Eye Care, PC, Detroit, Michigan, United States
Byers Eye Institute at Stanford University, Palo Alto, California, United States
Houston Eye Associates, The Woodlands, Texas, United States
Hospital St-Etienne, Saint-Priest-en-Jarez, France
Hospital Valence, Valence, France
Hospital Pellegrin, Bordeaux, France
Aravind Eye Hospital, Pondicherry, Tamil Nadu, India
Universitary Hospital, Nantes, Loire Atlantique, France
Price Vision Group, Indianapolis, Indiana, United States
University of Erlangen, Erlangen, Germany
The Center For Excellence in Eye care, Miami, Florida, United States
Harvard Eye Associates, Laguna Hills, California, United States
Ophthalmic Consultants of Boston, Waltham, Massachusetts, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.